Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Legend Biotech Corp ADR (NASDAQ: LEGN) closed the day trading at $32.88 down -0.15% from the previous closing price of $32.93. In other words, the price has decreased by -$0.15 from its previous closing price. On the day, 1.05 million shares were traded. LEGN stock price reached its highest trading level at $33.3113 during the session, while it also had its lowest trading level at $32.71.
Ratios:
For a better understanding of LEGN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.57 and its Current Ratio is at 4.71. In the meantime, Its Debt-to-Equity ratio is 0.37 whereas as Long-Term Debt/Eq ratio is at 0.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Redburn Atlantic on October 08, 2024, initiated with a Buy rating and assigned the stock a target price of $86.
On June 17, 2024, Truist started tracking the stock assigning a Buy rating and target price of $88.
H.C. Wainwright reiterated its Buy rating for the stock on May 24, 2024, while the target price for the stock was revised from $86 to $73.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 24 ’25 when Huang Ying bought 1,370 shares for $33.00 per share.
Huang Ying bought 1,357 shares of LEGN for $46,112 on Sep 23 ’25. On Sep 23 ’25, another insider, Yeung Jessie, who serves as the Officer of the company, bought 474 shares for $33.98 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LEGN now has a Market Capitalization of 6068684800 and an Enterprise Value of 11557726208. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.60 while its Price-to-Book (P/B) ratio in mrq is 5.86. Its current Enterprise Value per Revenue stands at 14.504 whereas that against EBITDA is -55.296.
Stock Price History:
The Beta on a monthly basis for LEGN is 0.24, which has changed by -0.2981857 over the last 52 weeks, in comparison to a change of 0.15535986 over the same period for the S&P500. Over the past 52 weeks, LEGN has reached a high of $51.77, while it has fallen to a 52-week low of $27.34. The 50-Day Moving Average of the stock is -11.28%, while the 200-Day Moving Average is calculated to be -6.44%.
Shares Statistics:
Over the past 3-months, LEGN traded about 1.27M shares per day on average, while over the past 10 days, LEGN traded about 1192470 shares per day. A total of 184.57M shares are outstanding, with a floating share count of 180.77M. Insiders hold about 2.06% of the company’s shares, while institutions hold 44.88% stake in the company. Shares short for LEGN as of 1756425600 were 7859738 with a Short Ratio of 6.21, compared to 1753920000 on 7822995. Therefore, it implies a Short% of Shares Outstanding of 7859738 and a Short% of Float of 8.140001.
Earnings Estimates
The stock of Legend Biotech Corp ADR (LEGN) is currently in the spotlight, with 5.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.0 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.08 and -$1.46 for the fiscal current year, implying an average EPS of -$0.68. EPS for the following year is $0.49, with 6.0 analysts recommending between $0.89 and $0.29.
Revenue Estimates
11 analysts predict $280.66M in revenue for. The current quarter. It ranges from a high estimate of $314.19M to a low estimate of $231.4M. As of. The current estimate, Legend Biotech Corp ADR’s year-ago sales were $160.21MFor the next quarter, 11 analysts are estimating revenue of $334.64M. There is a high estimate of $399.06M for the next quarter, whereas the lowest estimate is $280M.
A total of 17 analysts have provided revenue estimates for LEGN’s current fiscal year. The highest revenue estimate was $1.14B, while the lowest revenue estimate was $945.6M, resulting in an average revenue estimate of $1.05B. In the same quarter a year ago, actual revenue was $627.24MBased on 17 analysts’ estimates, the company’s revenue will be $1.59B in the next fiscal year. The high estimate is $1.95B and the low estimate is $1.45B.
